NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf400 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Margaret C Wheless und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, United States. Hauptthemen laut MEDLINE: Irinotecan, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, CCR NIH HHS.
Abstract (Originalsprache)
Background
Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage induced by cytotoxic chemotherapy. We aimed to assess the efficacy of ATR inhibitor, berzosertib, with irinotecan in patients harboring TP53-mutated, metastatic gastroesophageal cancer.
Methods
NCI 10211 is a phase II trial that enrolled patients with TP53-mutated, unresectable or metastatic gastroesophageal adenocarcinoma to receive berzosertib with irinotecan on day 1, 15 in 28-day cycles. Initially, patients who had progressed on at least 1 prior line of therapy were enrolled which was later amended to at least 2 prior lines of therapy. The primary outcome was objective response rate (ORR), and secondary outcomes included progression-free survival (PFS) and overall survival (OS). Nine patients underwent biopsy for correlative studies, which included assay evaluation of γH2AX, NBS1, and KAP1 p-Ser 824 expression.
Results
Of the 17 patients enrolled, 16 were evaluable for the primary endpoint of ORR. The ORR was 0%, disease control rate (DCR) of 56.2%, median PFS (mPFS) of 4.01 months, and median OS (mOS) of 6.21 months. The study did not meet its primary endpoint. The most common treatment-related adverse events were nausea (52.9%), anemia (41.2%), diarrhea (41.2%), and lymphopenia (41.2%) without any unexpected adverse events.
Conclusion
This novel combination of ATR inhibitor berzosertib with irinotecan did not lead to objective responses in patients with TP53-mutated, advanced gastroesophageal adenocarcinoma. The combination regimen was well tolerated without unexpected adverse events. This trial was registered with ClinicalTrials.gov (NCT03641313).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, United States.
- Florida Cancer Specialists and Research Institute, Largo, FL 33770, United States.
- Division of Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT 84112, United States.
- University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States.
- Department of Medicine, University of Pittsburgh Medical Center/Hillman Cancer Center, Pittsburgh, PA 15261, United States.
- UC Davis Comprehensive Cancer Center, Sacramento, CA 95817, United States.
ORCID-Profile: Margaret C Wheless, Farshid Dayyani, Jordan Berlin
Förderung
- NCI NIH HHS
- NIH HHS
- CCR NIH HHS
- National Institutes of Health
Zitieren
APA
Wheless, M. C., Stockton, S., Soares, H. P., Dayyani, F., Saeed, A., Kim, E., Jin, N., Yacoub, G., Florou, V., Ayers, G. D., Guerrouahen, B. S., Contreras, A., Li, L., Ferry-Galow, K. V., Gore, S., Das, S., & Berlin, J. (2025). NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyaf400
Vancouver
Wheless MC, Stockton S, Soares HP, Dayyani F, Saeed A, Kim E, et al. NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyaf400
BibTeX
@article{Wheless2025,
author = {Wheless, Margaret C and Stockton, Shannon and Soares, Heloisa P and Dayyani, Farshid and Saeed, Anwaar and Kim, Edward and Jin, Ning and Yacoub, George and Florou, Vaia and Ayers, Gregory D and Guerrouahen, Bella S and Contreras, Alejandro and Li, Li and Ferry-Galow, Katherine V and Gore, Steven and Das, Satya and Berlin, Jordan},
title = {NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf400}
}
EUVIMED